依达拉奉右莰醇联合替罗非班在急性缺血性脑卒中患者中的应用效果

Effectiveness of edaravone dexborneol combined with tirofiban in patients with acute ischemic stroke

摘要:

目的 探讨依达拉奉右莰醇联合替罗非班在急性缺血性脑卒中患者中的应用效果。方法 选取2021年1月—2024年1月华北医疗健康集团峰峰总医院邯郸院区收治的106例急性缺血性脑卒中患者，通过随机数字表法将患者分为对照组和观察组，各53例。对照组患者采用替罗非班治疗，观察组患者在对照组的基础上联合依达拉奉右莰醇，两组均治疗14 d。比较两组患者治疗前后的神经功能［美国国立卫生研究院卒中量表（NIHSS）评分、改良Rankin量表（mRS）评分］和认知功能［蒙特利尔认知评估量表（MoCA）评分］，以及脑血流状态［脑中动脉平均血流速度（Vm）、收缩期峰流速（Vs）、搏动指数（PI）］、血管内皮功能［血管内皮生长因子（VEGF）、一氧化氮（NO）、内皮素-1（ET-1）］、氧化应激指标［丙二醇（MDA）、超氧化物歧化酶（SOD）］、神经营养因子水平。结果 观察组治疗前后NIHSS、mRS和MoCA评分的差值均高于对照组（P <0.05）。观察组治疗前后Vm、Vs、PI的差值均高于对照组（P <0.05）。观察组治疗前后VEGF、NO、ET-1的差值均高于对照组（P <0.05）。观察组治疗前后MDA、SOD的差值均高于对照组（P <0.05）。观察组治疗前后GDNF、BDNF、NGF的差值均高于对照组（P <0.05）。结论 依达拉奉右莰醇联合替罗非班能提升患者的神经功能和认知能力，改善脑血流状态。

Abstract:

Objective To explore the effectiveness of edaravone dexborneol combined with tirofiban in patients with acute ischemic stroke.Methods The study included 106 patients with acute ischemic stroke admitted to the Handan Branch, Fengfeng General Hospital, North China Medical and Health Group from January 2022 to January 2024. Patients were divided into two groups by the random number table method, each with 53 individuals. The control group was treated with tirofiban alone, while the observation group received a combination of edaravone dexborneol and tirofiban. Both groups were treated for 14 days. Neurological function [National Institutes of Health Stroke Scale (NIHSS) score, Modified Rankin Scale (mRS) score], cognitive function [Montreal Cognitive Assessment (MoCA) score], cerebral blood flow parameters [mean flow velocity (Vm), peak systolic velocity (Vs), and pulsatility index (PI) of the middle cerebral artery], endothelial function [vascular endothelial growth factor (VEGF), nitric oxide (NO), endothelin-1 (ET-1) ], oxidative stress indicators [malondialdehyde (MDA), superoxide dismutase (SOD) ], and levels of neurotrophic factors were compared between the two groups before and after treatment.Results The differences of NIHSS, mRS, and MoCA scores before and after treatment were higher in the observation group than in the control group (P < 0.05). The differences of Vm, Vs and PI before and after treatment in the observation group were higher than those in the control group (P < 0.05). The differences of VEGF, NO and ET-1 levels before and after treatment in the observation group were higher than those in the control group (P < 0.05). The differences of MDA and SOD levels before and after treatment in the observation group were higher than those in the control group (P < 0.05). The differences of GDNF, BDNF and NGF levels before and after treatment in the observation group were also higher than those in the control group (P < 0.05).Conclusion Edaravone dexborneol combined with tirofiban enhances neurological function and cognitive performance while improving cerebral blood flow in patients with acute ischemic stroke.